erik, Please read sticky post 181. Posted six yea
Post# of 9122
Please read sticky post 181. Posted six years ago today
"we had the “game changer”"
The N-Assay technology and GBS testing
In this scenario involving capturing only 20 % of the US Group B Strep (GBS) market of 5 million tests annually, the total gross revenues are $200 million, production and operating costs $42.5 million and net revenues $157.5 million.
Read More: https://investorshangout.com/post/view?id=192...z6WSoGbmc5
So what happened to this game changer and why hasn't BB brought it to fruition?
I asked mac10, the author of 181, and got no response.
I asked numb1 and got no response.
I asked microcap and he answered me privately. If you want his answer ask him directly. He will probably answer you.
And now I will ask you about one of his failures.
So what happened to this game changer and why hasn't BB brought it to fruition?